### A. Once-lifetime screening with VIA/VILI at age 35 years

- **Age standardised progression rate from CIN3 to cancer:** 2.8%
- **Discount rate:** 0%
- **Mortality to incidence ratio:** 0.8
- **VIA cost:** $3.4
- **Screening participation:** 100%
- **Colposcopy accuracy:** 77% sensitivity for CIN2+
- **Rate of lost to follow-up:** -10%
- **Sensitivity of VIA for CIN2+**
- **5-year survival by FIGO stage:** +10%
- **LEEP success rate:** 100%
- **Cancer treatment cost (all FIGO stages):** $67.2
- **Proportion of CIN3 women treated by hysterectomy:** 5%
- **Screening test and colposcopy sensitivity for cancer:** 100%
- **Age specific rate of unsatisfactory visual tests:** 0%

### B. Once-lifetime screening with careHPV@0.5pg/mL at age 35 years

- **Age standardised progression rate from CIN3 to cancer:** 2.8%
- **Discount rate:** 0%
- **Mortality to incidence ratio:** 0.8
- **careHPV cost:** $10
- **Sensitivity of careHPV 0.5 self-sampling for CIN2+**
- **Colposcopy accuracy:** 77% sensitivity for CIN2+
- **Screening participation:** 100%
- **Rate of lost to follow-up:** -10%
- **5-year survival by FIGO stage:** +10%
- **LEEP success rate:** 100%
- **Cancer treatment cost (all FIGO stages):** $67.2
- **Proportion of CIN3 women treated by hysterectomy:** 5%
- **Screening test and colposcopy sensitivity for cancer:** 100%
- **Age specific rate of unsatisfactory visual tests:** 0%

### C. Routine screening with VIA/VILI at IARC-recommended screening intervals

- **Age standardised progression rate from CIN3 to cancer:** 2.8%
- **Discount rate:** 0%
- **Mortality to incidence ratio:** 0.8
- **VIA cost:** $3.4
- **5-year survival by FIGO stage:** -10%
- **Colposcopy accuracy:** 77% sensitivity for CIN2+
- **Screening participation:** 100%
- **Sensitivity of VIA for CIN2+**
- **Rate of lost to follow-up:** 5%
- **Screening test and colposcopy sensitivity for cancer:** 100%
- **Proportion of CIN3 women treated by hysterectomy:** 5%
- **LEEP success rate:** 100%
- **Cancer treatment cost (all FIGO stages):** $67.2
- **Proportion of CIN3 women treated by hysterectomy:** 5%
- **Screening test and colposcopy sensitivity for cancer:** 100%
- **Age specific rate of unsatisfactory visual tests:** 0%

### D. Routine screening with careHPV@0.5pg/mL at IARC-recommended screening intervals

- **Age standardised progression rate from CIN3 to cancer:** 2.8%
- **Discount rate:** 0%
- **Mortality to incidence ratio:** 0.8
- **careHPV cost:** $10
- **Sensitivity of careHPV 0.5 self-sampling for CIN2+**
- **Screening participation:** 100%
- **5-year survival by FIGO stage:** -10%
- **Rate of technically inadequate for careHPV:** 0%
- **Colposcopy accuracy:** 77% sensitivity for CIN2+
- **Rate of lost to follow-up:** 5%
- **LEEP success rate:** 100%
- **Cancer treatment cost (all FIGO stages):** $67.2
- **Proportion of CIN3 women treated by hysterectomy:** 5%
- **Screening test and colposcopy sensitivity for cancer:** 100%
- **LEEP cost:** $44.7
- **AGE specific rate of unsatisfactory visual tests:** 0%